New drug duo aims to control advanced liver cancer
NCT ID NCT04828486
Summary
This study tested a combination of two drugs, futibatinib and pembrolizumab, for people with advanced liver cancer that had spread and stopped responding to initial treatment. The goal was to see if the combination could help control the cancer's growth and extend the time before it worsened. Researchers also monitored side effects and quality of life for the 14 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.